The cost of an ebola case

Pathogens and Global Health

Volumn 109, Issue 1, 2015, Pages 4-9

  Bartsch, Sarah M ^a   Gorham, Katrin ^a   Lee, Bruce Y ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Computational modeling; Ebola; Economics

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EBOLA VIRUS; FEMALE; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MIDDLE AGED; MORTALITY; WORLD HEALTH ORGANIZATION; YOUNG ADULT; ECONOMICS; GUINEA; HEALTH CARE COST; HEMORRHAGIC FEVER, EBOLA; LIBERIA; SIERRA LEONE; THEORETICAL MODEL;

ADOLESCENT; ADULT; FEMALE; GUINEA; HEALTH CARE COSTS; HEMORRHAGIC FEVER, EBOLA; HUMANS; LIBERIA; MALE; MIDDLE AGED; MODELS, THEORETICAL; SIERRA LEONE; YOUNG ADULT;

EID: 84927644299     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/2047773214Y.0000000169     Document Type: Article

References (53)

1. WHO statement on the Meeting of the International Health Regulations Emergency Committee regarding the 2014 Ebola outbreak in West Africa. Geneva: World Health Organization; 2014.
2. Beigi RH, Wiringa AE, Bailey RR, Assi TM, Lee BY. Economic value of seasonal and pandemic influenza vaccina-tion during pregnancy. Clin Infect Dis. 2009;49(12):1784-92.
3. Lee BY, Bacon KM, Donohue JM, Wiringa AE, Bailey RR, Zimmerman RK. From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination. Vaccine. 2011;29(11):2149-58.
4. Lee BY, Bailey RR, Wiringa AE, Afriyie A, Wateska AR, Smith KJ, et al. Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza. Vaccine. 2010;28(37):5952-9.
5. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine. 2012;30(52):7443-6.
6. Lee BY, Ercius AK, Smith KJ. A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population. Vaccine. 2009;27(16): 2251-7.
7. The World Bank. The Economic impact of the 2014 Ebola epidemic: short and medium term estimates for guinea, Liberia, and Sierra Leone. Washington, DC: The World Bank; 2014.
8. Abkowitz A. Ebola treatment is very expensive. Businessweek [Internet]. 2014. Available from: http://www.businessweek.com/articles/2014-10-30/treatment-for-ebola-can-cost-up-to-500-000
9. Mcneil DG, Jr. Ask well: Ebola testing for all new arrivals? The New York Times [Internet]. 31 Octoebr 2014. Available from: http://well.blogs.nytimes.com/2014/10/25/ask-well-ebola-testing-for-all-new-arrivals/?_r50
10. Bill and Melinda Gates Foundation COmmits $50 Million to Support Emergency Response to Ebola 2014 October 31, 2014. Available from: http://www.gatesfoundation.org/Media-Center/Press-Releases/2014/09/Gates-Foundation-Commits-$50%20Millionto-Support-Emergency-Response-to-Ebola
11. Strom S. Paul Allen to give $100 million to tackle Ebola crisis. The New York Times [Internet]. 2014 October 31, 2014. Available from: http://www.nytimes.com/2014/10/24/business/paul-allen-to-give-100-million-to-tackle-ebola-crisis.html?_r50
12. Molinari NAM, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086-96.
13. Prevention and control of influenza with vaccines: recommen-dations of the Advisory Committee on Immunization Practices (ACIP), 2010. Atlanta, GA: Centers for Disease Control; 2010.
14. Beigi RH, Wiringa AE, Bailey RR, Assi TM, Lee BY. Economic value of seasonal and pandemic influenza vaccination during pregnancy. Clin Infect Dis. 2009;49:1784-92.
15. Brown ST, Tai JHY, Bailey RR, Cooley PC, Wheaton WD, Potter MA, et al. Would school closure for the 2009 H1N1 influenza epidemic have been worth the cost? A computational simulation of Pennsylvania. BMC Public Health. 2011;11(1):353.
16. Lee BY, Bacon KM, Donohue JM, Wiringa AE, Bailey RR, Zimmerman RK. From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination. Vaccine. 2011;29:2149-58.
17. Lee BY, Bailey RR, Wiringa AE, Afriyie A, Wateska AR, Smith KJ, et al. Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza. Vaccine. 2010;28:5952-9.
18. Lee BY, Bailey RR, Wiringa AE, Assi TM, Beigi RH. Antiviral medications for pregnant women for pandemic and seasonal influenza: an economic computer model. Obstetr Gynecol. 2009;114:971-80.
19. Lee BY, McGlone SM, Bailey RR, Wiringa AE, Zimmer SM, Smith KJ, et al. To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling. PLoS One. 2010;5(6):e11284.
20. Lee BY, Tai JHY, Bailey RR, McGlone SM, Wiringa AE, Zimmer SM, et al. Economic model for emergency use authorization of intravenous peramivir. Am J Managed Care. 2011;17(1):e1-9.
21. Lee BY, Wiringa AE. The 2009 H1N1 influenza pandemic: a case study of how modeling can assist all stages of vaccine decision-making. Hum Vaccines. 2011;7(1):115-9.
22. Clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker. 13 April 2014. Iterim emergency guidance — generic draft for West African adaptation. Geneva: WHO Press; 2014.
23. Interm list of WHO essential medicines necessary to treat Ebola cases based on existing guidelines. Geneva: World Health Organization; 2014.
24. Truven Health Analytics. MICROMEDX 2.0. Greenwood Village, CO: Turven Health Analytics; 2014 [updated 2014; cited 2014 Oct]. Available from: http://www.micromedexsolutions.com
25. WHO Ebola Response Team. Ebola virus disease in West Africa — the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371(16):1481-95.
26. World Health Organization. Personal protective equipment in the context of filovirus disease outbreak response. Rapid advance guideline. Geneva: World Health Organization; 2014.
27. World Health Organization. WHO interim list of personal protection equipement for infection and prevention control with focus on ebola classified by donation priority. Version 2. Geneva: World Health Organization; 2014.
28. World Health Organization. Ebola outbreak in west Africa: key message. Geneva: World Health Organization; 2014.
29. Global health observatory: country statistics. Geneva: World Health Organization; 2012 [updated 2014; cited 2014 Oct 22]. Available from: http://www.who.int/gho/countries/en/#M
30. World development indicators, 1960-2013. Washington, DC: The World Bank; 2014 [updated 2014; cited 2014 Oct]. Available from: http://data.worldbank.org/indicator/NY.GNP.PCAP.CD
31. Ebola response roadmap situation report: 10 December 2014. Geneva: World Health Organization; 2014.
32. Ebola response roadmap. Geneva: World Health Organization; 2014.
33. Carabin H, Edmunds WJ, Kou U, van den Hof S, Nguyen VH. The average cost of measles cases and adverse events following vaccination in industrialised countries. BMC Public Health. 2002;2:22.
34. Sicuri E, Vieta A, Lindner L, Constenla D, Sauboin C. The economic costs of malaria in children in three sub-Saharan countries: Ghana, Tanzania and Kenya. Malar J. 2013;12:307.
35. Schaetti C, Weiss MG, Ali SM, Chaignat CL, Khatib AM, Reyburn R, et al. Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar. PLoS Negl Trop Dis. 2012;6(10):e1844.
36. Kirigia JM, Sambo LG, Yokouide A, Soumbey-Alley E, Muthuri LK, Kirigia DG. Economic burden of cholera in the WHO African region. BMC Int Health Hum Rights. 2009;9:8.
37. Kim SY, Lee G, Goldie SJ. Economic evaluation of pneumo coccal conjugate vaccination in the Gambia. BMC Infect Dis. 2010;10:260.
38. Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe Tamfum JJ, Bressler D, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999;179(Suppl1):S28-35.
39. Bwaka MA, Bonnet MJ, Calain P, Colebunders R, de Roo A, Guimard Y, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis. 1999;179(Suppl 1):S1-7.
40. Kibadi K, Mupapa K, Kuvula K, Massamba M, Ndaberey D, Muyembe-Tamfum JJ, et al. Late ophthalmologic manifesta tions in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. J Infect Dis. 1999;179(Suppl1):S13-4.
41. de Roo A, Ado B, Rose B, Guimard Y, Fonck K, Colebunders R. Survey among survivors of the 1995 Ebola epidemic in Kikwit, Democratic Republic of Congo: their feelings and experiences. Trop Med Int Health. 1998;3(11):883-5.
42. African Health Observatory. Liberia: analytical summary. Geneva: World Health Orgainization; 2014. Available from: http://www.aho.afro.who.int/profiles_information/index.php/Liberia.Analytical_summary_-_Health_financing_system
43. Bausch DG, Sprecher AG, Jeffs B, Boumandouki P. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res. 2008;78(1):150-61.
44. Gulland A. First Ebola treatment is approved by WHO. BMJ. 2014;349:g5539.
45. World Bank Group. Ebola response fact sheet. Washington, DC: The World Bank; 2014.
46. ECRI Institute. Ebola PPE price index. Plymouth Meeting, PA: ECRI Institute; 2014 [updated 2014 Oct 30; cited 2014 Dec 11]. Available from: https://www.ecri.org/Pages/PPE.aspx
47. MSH. International drug price indicator guide 2013. Medford, MA: MSH; 2014 [updated 2013; cited 2014 Oct]. Available from: http://erc.msh.org/mainpage.cfm?file51.0.htm&module5DMP&language5English
48. ACFS growth chart: South Africa. Normanton: ACSF; 2014.
49. United Nations, Department of Economic and Social Affairs, Population Division. World population prospects: the 2012 revision, DVD Edition 2013. New York: United Nations; 2013.
50. Walpole SC, Prieto-Merino D, Edwards P, Cleland J, Stevens G, Roberts I. The weight of nations: an estimation of adult human biomass. BMC Public Health. 2012;12:439.
51. McCoy D, Bennett S, Witter S, Pond B, Baker B, Gow J, et al. Salaries and income of health workers in sub-Saharan Africa. Lancet. 2008;371:675-81.
52. World Health Organization. Benin comprehensive multiyear plan 2009-2013. Geneva: World Health Organization; 2009.
53. World Health Organization. Niger comprehensive multiyear plan 2011-2015. Geneva: World Health Organization; 2010.